Prostate Cancer | Specialty

Denosumab Safe, Effective in Increasing Bone Density in Nonmetastatic Prostate Cancer

December 11th 2018

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

Dr. Vaena on the Importance of Risk Stratification in Prostate Cancer

December 11th 2018

Daniel Vaena, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of risk stratification in prostate cancer.

An Explorer's Mentality Leads to Novel Treatments in Prostate and Bladder Cancer

December 10th 2018

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.

Dr. Fowke on Overcoming Racial Disparity in Prostate Cancer

December 7th 2018

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses ways to overcome racial disparity in prostate cancer.

Dr. Slovin on ADT-Associated Cardiac Complications in Prostate Cancer

December 4th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses androgen receptor therapy (ADT)-associated cardiac complications in prostate cancer.

San Diego Urology Group Enjoys Growth in a Tough Market

November 30th 2018

Genesis Healthcare Partners, the region’s largest independent urology practice, is challenged by regulatory changes and the dominance of the regional managed care market, which has huge control of patient flow and payment structures.

What Lies Ahead in Urology

November 30th 2018

Raoul S. Concepcion, MD, FACS, discusses considerations for urologists in this new era.

Dr. Emberton on the Importance of Multidisciplinary Care in Prostate Cancer

November 30th 2018

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.

Sifting for Relevance Among Germline Mutations in Prostate Cancer

November 29th 2018

Up to 30% of men with prostate cancer could meet criteria for genetic evaluation for hereditary disease. The challenge is separating the mutations that are relevant from those that are not.

Dr. Bradley on Next Steps for Research in Nonmetastatic Prostate Cancer

November 29th 2018

Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.

Dr. Kearns on AEs Associated With Surgery in Prostate Cancer

November 29th 2018

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate Cancer

November 28th 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.

Chemotherapy for BRCA-Mutated Prostate Cancer

November 27th 2018

PARP Inhibitors in Advanced Prostate Cancers

November 27th 2018

Genotyping in Prostate Cancer

November 27th 2018

Therapeutic Sequencing for CRPC Based on Recent Data

November 27th 2018

Earlier Detection of Prostate Cancer Bone Metastases

November 27th 2018

Assessment of Bone Health in Prostate Cancer

November 27th 2018

ERA 223 and Implications for Clinical Practice

November 27th 2018

Effect of Prostate Cancer Therapies on Bone Metabolism

November 27th 2018